Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
:OTLK
OTLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $8.32
Previous CloseN/A
Volume358.39K
Average Volume (3M)1.54M
Market Cap
$131.93M
Enterprise Value$84.93M
Total Cash (Recent Filing)$7.56M
Total Debt (Recent Filing)$33.32M
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Dec 18, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding44,419,530
10 Day Avg. Volume2,896,195
30 Day Avg. Volume1,540,419
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue499.21
Enterprise Value/Gross Profit-56.13K
Enterprise Value/Ebitda5.24
Forecast
1Y Price Target
$3.00Price Target Upside1.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesThe current valuation is seen as attractive, representing significant upside potential if the FDA approves ONS-5010.
Product Launch SuccessInitial sales of Lytenava are encouraging, generating a decent quarterly revenue since its launch in Germany and UK.
Regulatory ApprovalManagement is confident in Lytenava's ability to compete effectively in both countries given its regulatory approval and price advantage.
Bears Say
Manufacturing RisksChemistry, manufacturing and controls issue is another risk factor as it has increasingly come up as a bottleneck in recent approval delays.
Regulatory ChallengesConcerns remain about whether the BLA resubmission of ONS-5010 is sufficient to secure an FDA approval.
Regulatory FeedbackThe FDA issued a Complete Response Letter (CRL) for ONS-5010 due to several CMC issues and a lack of substantial evidence.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.87 and its highest was $8.32 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $131.93M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Dec 18, 2025 which is in 113 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.088.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 44,419,530 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went up 14.085%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (1.01% Upside)
$3.00 (1.01% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-60.55%
12-Months-Change
Fundamentals
Return on Equity
<0.01%
Trailing 12-Months
Asset Growth
-52.45%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$3.00
▲(1.01% Upside)
Technical Analysis
Ownership Overview
32.94% Insiders
3.05% Mutual Funds
0.45% Other Institutional Investors
60.55% Public Companies and
Individual Investors